Artemisinin-based treatments (ACTs) are the main treatment used to handle the malaria disease produced by P. falciparum, but recently evidence shows that some strains of P. falciparum are less susceptible to ACT. We will reanalyze data of transcriptomic and metabolomic approaches available about strains of P. falciparum that have resistance to ACT. The goal is to build metabolic pathways that can explain how the parasite tolerates oxidative stress caused by artemisinin.